OncoMatch/Clinical Trials/NCT07037680
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Is NCT07037680 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Anlotinib for locally advanced non-small cell lung cancer.
Treatment: Anlotinib — Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti-angiogenesis therapy (Anlotinib) during radiotherapy course.We hypothesize that the combination of radiotherapy with anlotinib could improve the 2-year PFS rate from 35% with sCRT to 50. The accrual target was 44 patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic chemotherapy
Received systemic chemotherapy or combined chemotherapy and immumitherapy for ≥ 4 weeks without progression
Cannot have received: thoracic radiotherapy
thoracic radiotherapy history ... within three months
Lab requirements
Kidney function
adequate renal function with a negative urine protein
Liver function
adequate hepatic function
Adequate hepatic and renal functions with a negative urine protein
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify